Current Management of Relapsed Acute Myeloid Leukemia
Source: A Focus on AML: Applying the Latest Research to Individualize Therapy

Video

Now Playing...
In this on-demand Webcast, Harry P. Erba, MD, provides expert perspective on optimal treatment of patients with acute myeloid leukemia.

Harry P. Erba, MD, PhD, has disclosed that he has received consulting fees from Amgen, Ariad, Celgene, Daiichi Sankyo, Glycomimetics, Incyte, Novartis, Pfizer, Seattle Genetics, and Sunesis; funds for non-CME/CE services from Incyte and Novartis; and funds for research support from Agios, Amgen, Astellas, Celator, Janssen, Juno, Seattle Genetics, and Takeda Oncology.

Downloads

  • Current Management of Relapsed Acute Myeloid Leukemia